Popular search terms:

CSL Behring UK News and Stories

Diversity: Good for our people and patients

When you work at a leading global biotech company with more than 27,000 employees, serving patients in more than 100 countrie…

09 Dec 2020

Chief Scientific Officer Andrew Nash speaks at a meeting before the pandemic

Research is tough, success is stupendous

Andrew Nash, CSL’s Chief Scientific Officer, is a busy man. He has his arms around 25 or 30 ongoing research projects spannin…

09 Dec 2020

Introducing Emil von Behring

The scientist who put the ‘Behring’ into CSL Behring won the first Nobel Prize for medicine.

09 Dec 2020

See All News and Stories

Focus on Rare Diseases

CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in our support of programmes and activities for patients with rare plasma-protein related diseases, including bleeding disorders and primary immune deficiencies.

Adverse Event Reporting

Adverse events should be reported.

Reporting forms and information can be found at https://yellowcard.mhra.gov.uk . Adverse events should also be reported to CSL Behring UK Ltd. on 01444 447 405.

If you would like to contact CSL Behring for any other reason, please visit our Contact page to find the appropriate details.

Statement on Modern Slavery

CSL Behring views modern slavery as a serious and ongoing concern. Our Modern Slavery Statement explains what we are doing to combat it. You can read the statement here.

GBR-CRP-0179 July 2021

How did it all start? Learn more about the roots of CSL Behring.

Discover our commitment to funding research and development of new medicines.

Take a look at the range of products we offer here in the UK.

CSL Behring UK News and Stories

Focus on Rare Diseases

Adverse Event Reporting